| Guillain-Barre syndrome (GBS) is an autoimmue disease of the peripheral nervous system and histopathologically characterized by infiltration of lymphocytes and macrophages and local demyelination of sciatic nerves. Experimental Autoimmune Neuritis (EAN) is the well known animal model of Guillain-Barre syndrome, and both of them possess similar clinical features, electrophysiological, pathological and immunological characteristics. The study of clinical application of interferon-beta (IFN-β) to EAN may provide novel strategies for the treatment of GBS.Establishment of EAN and assessment of clinical signsA total of 90 adult, healthy , male guinea pigs were randomly divided into control group, PBS treated group and IFN-β treated group. The animals in PBS treated group and IFN-P treated group were immunized by injection into both hind footpads with 500μl of inoculum containing 0.5 mg myelin basic protein (MBP), which was isolated from bovine sciatic nerves and emulsified in 500μl Freund's Complete Adjuvant. Ten days later the animals were immunized again with the compound of MBP and Freund's Incomplete Adjuvant. Clinical scores were assessed according to Gabriel Scale.Clinical assessment of EAN before and after treatmentClinical assessments were carried out on day1 before treatment, day 7 after treatment and day 14 after treatment, respectively. Electrophysiological characteristics were assessed by examining the latency, amplitude and conduction velocity of evoked...
|
PDF Full Text Request